openPR Logo
Press release

Hoth Therapeutics, Inc. (NASDAQ: HOTH) Makes Headlines With Rapid Tumor Kill Data

09-02-2025 03:32 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Hoth Therapeutics, Inc. (NASDAQ: HOTH) Makes Headlines With

Biotech is once again capturing investor attention, with small-cap companies in particular drawing focus for their potential to deliver breakthrough therapies and regulatory milestones. Over the past six months, clinical-stage biotechs reporting meaningful data have moved an average of nearly 12 percent in a single day, showing how quickly the market reacts to progress. With multiple programs across oncology, supportive care, and metabolic disease advancing toward key readouts, the sector is generating a steady stream of opportunities for investors seeking high-impact growth. In this environment, emerging companies with robust pipelines are worth watching closely.

Hoth Therapeutics (NASDAQ: HOTH): Fresh Data Puts HT-KIT in the Spotlight

Earlier today, Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced compelling new preclinical findings for HT-KIT, its antisense candidate targeting mutant KIT mRNA. The data showed potent anti-tumor activity, a clean safety profile, and regulatory-grade bioanalytical validation that surpassed international standards, giving investors a timely reason to pay attention.

HT-KIT: Rapid Tumor Kill and Regulatory Validation

In models of gastrointestinal stromal tumors and systemic mastocytosis, HT-KIT triggered significant tumor cell death within 24 hours and measurable tumor shrinkage by day eight. The candidate also achieved more than 80 percent knockdown of KIT expression in vitro, a strong signal against one of the most persistent oncogenic drivers.

Equally important, multi-dose safety studies confirmed no off-target toxicity across critical organs, including the liver, kidneys, spleen, bone marrow, and thymus. A dose-dependent biological signal was observed, with proportional organ engagement and no gross pathology at any site.

The preclinical program was validated under OECD, FDA, and EMA GLP standards by Altasciences Company, Inc. Results exceeded regulatory benchmarks, with 90.5 percent reproducibility in incurred sample reanalysis compared to the 66.7 percent minimum and serum stability for 37 days, extending beyond the 28-day requirement. No protocol deviations affected study reliability, strengthening the case for clinical advancement.

Chief Executive Officer Robb Knie called the results a rare and powerful story, combining tumor kill within 24 hours, safety across all systems, and reproducibility beyond regulatory standards. Hoth Therapeutics plans to integrate the data into its formal toxicology package as it prepares for an IND submission and potential first-in-human trials.

HT-001: Advancing in Oncology Supportive Care

While HT-KIT now takes center stage, Hoth Therapeutics is also moving forward with HT-001, a topical treatment for skin toxicities caused by epidermal growth factor receptor inhibitors in cancer patients. In July, the company partnered with ICON Clinical Research to expand its Phase II trial into Europe, with regulatory approval expected in as many as three countries. The trial is already enrolling patients in the United States.

Expanding into Europe not only accelerates enrollment but also positions the program for a potential global Phase III study. By alleviating the harsh dermatologic side effects of EGFR inhibitors, HT-001 could allow patients to remain on essential cancer therapies longer, improving both quality of life and treatment outcomes.

Targeting Obesity and Liver Disease with GDNF

Beyond oncology, Hoth Therapeutics is pursuing an ambitious strategy in metabolic disease. On July 22, the company entered into a Cooperative Research and Development Agreement with the U.S. Department of Veterans Affairs and the Foundation for Atlanta Veterans Education and Research to evaluate glial cell-derived neurotrophic factor as a therapy for obesity and fatty liver disease.

The study will benchmark GDNF directly against semaglutide, today's leading weight loss drug, in both obese mice and human liver chimeric models. The goal is to assess effects on weight reduction, liver health, and insulin sensitivity. All protocols are IRB approved and comply with federal research ethics standards.

This initiative builds on a June announcement that Hoth Therapeutics and Silo Pharma signed a letter of intent to form a 50-50 joint venture around the same GDNF technology, which was co-developed by the VA and Emory University. The program targets obesity, nonalcoholic fatty liver disease, and type 2 diabetes, conditions with a combined global market estimated at 16 billion dollars.

Why Investors Are Watching

Hoth Therapeutics has steadily expanded its story beyond early potential. HT-KIT's new preclinical findings provide a timely catalyst, demonstrating both efficacy and safety alongside regulatory-ready validation. HT-001 is advancing through a Phase II trial that now spans the U.S. and Europe, while the GDNF platform has secured high-profile partnerships with both the VA and Silo Pharma.

For a small-cap company, this combination of oncology innovation, supportive care development, and bold moves in metabolic disease is significant. With multiple milestones ahead including an IND for HT-KIT, expanded trial data for HT-001, and preclinical readouts for GDNF, Hoth Therapeutics, Inc. (NASDAQ: HOTH), has positioned itself as a name worth keeping on the biotech watchlist.

Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by Awareness Consulting Network LLC to assist in the production and distribution of content related to HOTH. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.

Media Contact
Company Name: RazorPitch
Contact Person: Mark McKelvie
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hoth-therapeutics-inc-nasdaq-hoth-makes-headlines-with-rapid-tumor-kill-data]
City: NAPLES
State: Florida
Country: United States
Website: https://razorpitch.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hoth Therapeutics, Inc. (NASDAQ: HOTH) Makes Headlines With Rapid Tumor Kill Data here

News-ID: 4166943 • Views:

More Releases from ABNewswire

Honoring Her: The First Mother's Day Without Mom Gift - Giftlips
Honoring Her: The First Mother's Day Without Mom Gift - Giftlips
Image: https://www.abnewswire.com/upload/2025/10/b846bcb75dad8a71c2b8a90b1eb0a0d1.jpg New York City - Mother's Day, a time typically filled with joy and celebration, can evoke a profound sense of emptiness and longing for those experiencing their first Mother's Day without mom. This poignant milestone brings a unique set of emotions, often amplifying the process of grief. Recognizing this delicate period, GiftLips offers guidance and a compassionate tool to help individuals navigate this challenging day by transforming sorrow into meaningful
Hoodies Launches Men's Streetwear for Fall: The Ultimate Guide to Autumn Outfits
Hoodies Launches Men's Streetwear for Fall: The Ultimate Guide to Autumn Outfits
The first chill of fall hits, you reach for your hoodie. The crisp air, warm tones, and layering options make autumn the perfect time to experiment with style. From oversized hoodies to rugged boots, men's streetwear in fall balances comfort and edge. This season lets you mix textures, play with earthy colors, and express personality through versatile outfits. If you're heading to casual hangouts, city streets, or stylish nights out,
Music City Timepieces Expands Luxury Watch Portfolio as Nashville's Top Veteran-Owned Dealer
Music City Timepieces Expands Luxury Watch Portfolio as Nashville's Top Veteran- …
As Nashville's leading watch dealer, this veteran-owned retailer delivers authenticated luxury timepieces with the confidence of guaranteed best pricing. Image: https://www.abnewswire.com/upload/2025/10/9e72a99710da4ea5fed798ac9088113f.jpg Music City Timepieces ("MCTP"), recognized as Nashville's top watch dealer and a proud veteran-owned retailer, today announced the expansion of its portfolio of authenticated fine timepieces. The company's growing collection now includes luxury names such as Rolex, Audemars Piguet, Patek Philippe, Richard Mille, Cartier, IWC, Omega, Tudor, and more, delivering world-class
Best Local Carpenter in North Jutland - More Than Just a Shed Builder
Best Local Carpenter in North Jutland - More Than Just a Shed Builder
Rasmus Guldhammer delivers everything you need. North Jutland is home to a wide range of skilled carpentry and construction companies. But when it comes to personal service, quick response, and solid craftsmanship, Master Carpenter Rasmus Guldhammer along with MT Hojgaard, A. Enggaard A/S, NCC, MT Byg & Entreprise are especially noteworthy. For many years, he has distinguished himself as the small local company delivering big results - building a reputation that private

All 5 Releases


More Releases for Hoth

Microbe-killing Topical Market 2025: Growth, Applications, Innovations and Busin …
The microbe-killing topical industry has witnessed remarkable transformations driven by rising consumer awareness around hygiene and infection prevention. Increasing incidences of skin infections and the growing need for safe and effective antimicrobial solutions have propelled innovation and adoption across healthcare, cosmetics, and personal care sectors. The Global Microbe-killing Topical Market size is estimated to be valued at USD 4.38 billion in 2025 and is expected to reach USD 7.16 billion
EGFR Inhibitors-Induced Skin Disorders Market Growth Projections 2024-2034: Delv …
DelveInsight's "EGFR Inhibitors-Induced Skin Disorders Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the EGFR Inhibitors-Induced Skin Disorders, historical and forecasted epidemiology as well as the EGFR Inhibitors-Induced Skin Disorders market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the EGFR Inhibitors-Induced Skin Disorders market outlook, drug uptake, treatment scenario and epidemiology trends, Click
Cutaneous Lupus Erythematosus (CLE) Market Set to Experience Unprecedented Growt …
DelveInsight's "Cutaneous Lupus Erythematosus (CLE) Patient Pool Analysis, Market Size and Market Forecast APAC, 2034" report delivers an in-depth understanding of Cutaneous Lupus Erythematosus (CLE), historical and forecasted epidemiology as well as the Cutaneous Lupus Erythematosus (CLE) market trends in the India, China, South Korea, Taiwan, and Australia. The Cutaneous Lupus Erythematosus (CLE) market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the
Microbe-killing Topical Market to Witness Comprehensive Growth 2023-2030| Hoth T …
"Worldwide Market Reports offers 𝐔𝐩𝐭𝐨 𝟕𝟎% 𝐝𝐢𝐬𝐜𝐨𝐮𝐧𝐭 on Microbe-killing Topical Market Reports on Single User Access and Unlimited User Access" The report discusses everything a marketer requires before investing in the global Microbe-killing Topical during the forecast period 2023-2030. It provides detailed insight into current trends, shares, size, and sales value and volume. The data used for this report is obtained from reliable industry sources, paid resources, and validated sources. This
Blog Writing Service Market is Booming Worldwide | Craftive Content, BRAFTON, Th …
Latest Study on Industrial Growth of Blog Writing Service Market 2022-2027. A detailed study accumulated to offer Latest insights about acute features of the Blog Writing Service market. The report contains different market predictions related to revenue size, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends
Review Management Software Market Is Likely to Experience a Tremendous Growth by …
This Review Management Software market report contains details about the industrial environment, market segmentation, channel characteristics and sourcing situation. From complex classifications, layouts, and purposes to a simple overview of the sector, this market research report covers it all. One of the most essential things to keep in mind in order to thrive in this competitive industry is to have a firm grasp on the business strategy that emerges. This